Document is current
Any future updates will be listed below
-
Authors
Rashid, Rumana
Chen, Yu-An https://orcid.org/0000-0001-7228-4696
Hoffer, John
Muhlich, Jeremy L. https://orcid.org/0000-0002-0811-637X
Lin, Jia-Ren https://orcid.org/0000-0003-4702-7705
Krueger, Robert
Pfister, Hanspeter
Mitchell, Richard
Santagata, Sandro https://orcid.org/0000-0002-7528-9668
Sorger, Peter K. https://orcid.org/0000-0002-3364-1838
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54-CA225088, U2C-CA233262, P30-CA06516, U54-CA225088, U2C-CA233262, U2C-CA233280, P30-CA06516)
Ludwig Center at Harvard, Ludwig Institute for Cancer Research
- License Information
-
More Information
Article History
Received: 13 March 2020
Accepted: 2 June 2021
First Online: 8 November 2021
Competing interests
: P.K.S. is a member of the SAB and BOD member of Applied Biomath, RareCyte Inc., and Glencoe Software, which distributes a commercial version of the OMERO database. P.K.S. is also a member of the NanoString SAB. In the past 5 years, the Sorger Laboratory has received research funding from Novartis and Merck. P.K.S. declares that none of these relationships have influenced the content of this manuscript. S.S. is a consultant for RareCyte Inc. The remaining authors declare no competing interests.
